Managing cancer-related anaemia in congruence with the EORTC guidelines is an independent predictor of haemoglobin outcome: Initial evidence from the RESPOND study-Reference-Cited by-同舟云学术

Managing cancer-related anaemia in congruence with the EORTC guidelines is an independent predictor of haemoglobin outcome: Initial evidence from the RESPOND study

Published:2009-01 Issue:1 Volume:45 Page:8-11
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Aapro Matti,Van Erps Joanna,MacDonald Karen,Soubeyran Pierre,Muenzberg Michael,Turner Matthew,Warrinnier Hans,Albrecht Tara,Abraham Ivo

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference6 articles.

1. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer;Bokemeyer;Eur J Cancer,2004

2. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update;Bokemeyer;Eur J Cancer,2007

3. Promoting evidence-based management of anemia in cancer patients: background, development, and scientific validation of RESPOND, a web-based clinical guidance system based on the EORTC guidelines;Aapro;Crit Rev Oncol Hematol,2008

4. Intraclass correlation metrics for the accuracy of algorithmic definitions in a computerized decision support system for supportive cancer care;Aapro;Support Care Cancer,2007

5. Van Erps J, Aapro M, MacDonald K, et al. Promoting evidence-based management of anemia in cancer patients: concurrent, and discriminant validity of RESPOND, a web-based clinical guidance system based on the EORTC guidelines [submitted for publication].

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Anemia, Thrombosis, Transfusion Therapy, and Cancer Outcomes;Perioperative Care of the Cancer Patient;2023

2. Psychological and Financial Distress Management in Adults With Acute Leukemia;Seminars in Oncology Nursing;2019-12

3. Erythropoietin and Cancer: The Unintended Consequences of Anemia Correction;Frontiers in Immunology;2014-11-11

4. Modeling of treatment response to erythropoiesis-stimulating agents in older (age≥70years) and younger (age<70years) patients with cancer and anemia: Findings from the Anemia Cancer Treatment study;Journal of Geriatric Oncology;2013-04

5. Comparative cost efficiency across the European G5 countries of originators and a biosimilar erythropoiesis-stimulating agent to manage chemotherapy-induced anemia in patients with cancer;Therapeutic Advances in Medical Oncology;2012-04-12